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Abstract 
Here we report a new and efficient approach
of macrophage specific drug delivery by coat-
ing liposomes with albumin. Activated albumin
was reacted with liposomes containing poly-
ethylene glycol (PEG) as hydrophilic spacers to
create a flexible layer of covalently bound albu-
min molecules on the liposome surface.
Albumin coated liposomes were taken up
faster and more efficiently than uncoated lipo-
somes by murine macrophages. Liposome
uptake was significantly higher in macropha -
ges as compared to other cell types tested
(endothelial cells, fibroblasts, tumor cells),
suggesting specificity for macrophages. In
vivo, splenic macrophages phagocytosed BSA
coated liposomes (BSA-L) at faster rates com-
pared to conventional liposomes (L) and PEG
liposomes (PEG-L). To prove the effectiveness
of this new macrophage specific drug carrier,
the bisphosphonates clodronate and zole-
dronate were encapsulated in BSA-L and com-
pared with conventional liposomes. In vitro,
treatment of macrophages with clodronate or
zoledronate in BSA-L led to cytotoxic activity
within a very short time and to up to 50-fold
reduced IC50 concentrations. In vivo, clo-
dronate encapsulated in BSA-L depleted
splenic macrophages at a 5-fold lower concen-
tration as conventional clodronate-liposomes.
Our results highlight the pharmaceutical ben-
efits of albumin-coated liposomes for
macrophage specific drug delivery. 
Introduction
Cells with phagocytic properties have been
subject of investigation since their discovery
by Metchnikoff more than a decade ago.1
However, only the advent of modern technolo-
gies has made it possible to recognize the
diverse roles macrophages play in an organ-
ism. Besides their homeostatic properties
macrophages are the gate keepers of the
immune system and they recognize and elimi-
nate senescent and abnormal cells and gener-
ate signals that influence growth, differentia-
tion and death of cells.1-3 Several disorders like
arthritis, atherosclerosis, asthma, inflammato-
ry bowel disease and others origin from the
pathological activity of macrophages, condi-
tions also considered as chronic inflamma-
tion.4-8 Microorganisms such as M. tuberculo-
sis,9,10 parasites11,12 and viruses such as HIV13-16
take advantage of macrophages as safe haven
or powerful allies. In cancer, tumor associated
macrophages contribute considerably to tumor
growth and disease severity in many solid
tumors.17-19 Given the central role macrophages
play in this variety of human diseases, effec-
tive targeting of drugs to these cells could be
an astute strategy for efficacious prevention
and treatment of infectious and inflammatory
diseases and cancer. 
A multitude of options to deliver drugs to
macrophages have been developed in the
past.20 Most extensively studied are liposomes
- nanosized unilamellar phospholipid bilayer
vesicles.21,22 Consequently, many drugs
involved in macrophage-associated disorders
have been studied using liposomes as carrier. 
One of the most frequently reported applica-
tion of macrophage specific liposome-mediat-
ed drug delivery are clodronate-liposomes that
are successfully used to suppress macrophage
activity by their depletion in various models of
autoimmune diseases, transplantation, neuro-
logical disorders, viral and bacterial infections
and cancer. Surprisingly, although effective in
macrophage depletion, these liposomes have
not been optimized for specific macrophage
uptake, as they are composed of phosphatidyl-
choline and cholesterol, carry neutral charges
and are either multilamellar or small unilamel-
lar vesicles.23-26 Hence, to enhance macrophage
uptake, we introduced a non-specific modifica-
tion by linking albumin to liposomes.
Liposomes are recognized by macrophages by
their opsonization, which is a process where
serum proteins, in particular proteins of the
complement system, attach to the liposome
surfaces to facilitate recognition and phagocy-
tosis.27-33 Therefore, we reasoned that protein-
coated and thus negatively charged liposomes
would be phagocytosed more efficiently than
conventional uncharged liposomes. We
achieved this artificial opsonization by cova-
lent attachment of albumin to the distal end of
flexible poly (ethylene glycol) modified lipo-
somes. Here we provide first proof of principle
that albumin coated small unilamellar lipo-
somes are a highly efficient drug delivery sys-
tem for macrophages. Using fluorescence
based approaches we noticed massive increase
in uptake by macrophages when compared
with conventional liposomes and with other
cell types. Consequently, encapsulation of bis-
phosphonates in albumin coated liposomes led
to a significant decrease of the cytotoxic dose
and to more effective macrophage depletion in
vivo.
Materials and Methods
Chemicals
Soy phosphatidylcholine (SPC) was from L.
Meyer, Hamburg, GE and 1.2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-(malei -
mide (polyethylene glycol)2000) (DSPE-PEG-
Mi) from Avanti Polar Lipids (Alabaster,
Alabama, USA). Cholesterol (Chol), human
serum albumin (HSA), N-ethylmaleimide and
cysteine were from Fluka, Switzerland. D,L α-
tocopherol (α-toc) and mannitol from Merck
(Darmstadt, Germany). 1,1’-dioctadecyl-
3,3,3’,3’-tetramethyl-indocarbocyanine per-
chlorate (DiI) was from Molecular Probes
(Invitrogen, Carlsbad, CA, USA). Hydroxyla -
mine chloride, murine (MSA) and bovine
serum albumin (BSA) were from Sigma-
Aldrich (St. Louis, MO, USA). Clodronate was
a gift from Farchemia SrL (Treviglio, Italy)
and zoledronate a gift from Novartis
International (Basel, Switzerland). N-succin-
imidyl-S-acetyl-thioacetate (SATA) was pre-
pared as described.29Liposome preparation
All liposomes were prepared by freeze-thaw-
ing and high pressure extrusion as
Nanotechnology Development 2011; volume 1:e2
Correspondence: Reto Schwendener, 
Institute of Molecular Cancer Research,
University of Zurich, Winterthurerstr. 190, CH-
8057 Zurich, Switzerland. 
Tel. +41.44.635 3483 - Fax: +41.44.635 3484. 
E-mail: rschwendener@imcr.uzh.ch
Key words: albumin coated liposomes,
macrophage, specific targeting, drug delivery,
bisphosphonates.
Acknowledgment: this work was supported in part
by Novartis, Basel, Switzerland. The authors wish
to thank Dr. Stefanie Krämer for help with the
zeta-potential measurements.
Contributions: RS, CV, SK, study conception and
manuscript writing; CV, SK, experiments and
data analysis; SK, manuscript revising.
Conflict of interest: the authors report no con-
flicts of interest. 
Received for publication: 10 May 2011.
Accepted for publication: 18 July 2011.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright C. Vuarchey et al., 2011
Licensee PAGEPress, Italy
Nanotechnology Development 2011; 1:e2
doi:10.4081/nd.2011.e2
No
n-c
om
erc
ial
us
e o
nly
[Nanotechnology Development 2011; 1:e2] [page 5]
described.24 Lipid compositions were as fol-
lows: (i) Conventional liposomes (L), SPC 104
µmol/mL (80 mg/mL), Chol 20 µmol/mL (8
mg/mL), α-toc 1.04 µmol/mL (0.45 mg/mL);
(ii) PEG-liposomes (PEG-L) and albumin coat-
ed liposomes (BSA-L, MSA-L, HSA-L), SPC 104
µmol/mL, Chol 20 µmol/mL, α-toc 1.04
µmol/mL, DSPE-PEG-Mi 2.1 µmol/mL (6
mg/mL); (iii) Conventional clodronate (CL)
liposomes, SPC 130 µmol/mL (100 mg/mL),
Chol 25 µmol/mL (10 mg/mL), α-toc 1.3
µmol/mL (0.56 mg/mL) and (iv) PEG clo-
dronate (PEG-CL) liposomes and BSA coated
clodronate (BSA-CL) liposomes, SPC 130
µmol/mL, Chol 25 µmol/mL, α-Toc 1.3
µmol/mL, DSPE-PEG-Mi 2.6 µmol/mL (7.3
mg/mL). For fluorescent liposomes DiI was
added at 0.35 µmol/mL (0.3 mg/mL).
Lipids were dissolved in methanol/methyl-
ene chloride (1:1, v/v) and solvents removed
by evaporation at 40°C (Rotavapor, Büchi
Labortechnik AG, Flawil, Switzerland). Dried
lipid films were dispersed in phosphate-man-
nitol buffer (PB-Man, 20 mM phosphate, 230
mM mannitol, pH 7.4), supplemented with
66.25 mg/mL clodronate or 4 mg/mL zole-
dronate for the bisphosphonate liposomes.
Liposomes were obtained by three cycles of
freeze-thawing in liquid nitrogen and 40°C
water, followed by repetitive extrusion
through NucleporeTM membranes (Sterico
AG, Dietikon, Switzerland) of 400 nm (3x) and
100 nm (8x) pore size using a Lipex™ extrud-
er (Northern Lipids Inc., Burnaby, BC,
Canada). For the clodronate liposomes (3 and
4) extrusion was done with 400 nm filters (8x)
and non-encapsulated biphosphonate was
removed by extensive dialysis (Spectrapore
tube, 12-14 kD mol.wt. cut-off) using PB-Man
as dialysis buffer (1:100, v/v). All preparations
were sterile filtrated (0.45 μm Millex-HV fil-
ters, Millipore, Billerica, MA, USA). Liposome
size and homogeneity were measured by
dynamic laser light scattering (Nicomp 370,
Nicomp Corp., Santa Barbara, CA, USA). The
ζ-potential was determined with a Malvern
Zetasizer 3000 HAS (Malvern Instruments,
Malvern, UK) and bisphosphonate encapsula-
tion assessed by liquid scintillation counting
(Tri-Carb, Canberra Packard Int., Zurich,
Switzerland).Albumin coupling
Albumins were coupled to the liposomes as
described.34 Thiolation was performed by mod-
ification of earlier described methods.35 SATA
(1 mg) dissolved in dimethylformamide (100
µL) was added per ml albumin solution (10
mg/mL) and incubated 1h at RT in HEPES
buffer (10 mM HEPES, 145 mM NaCl, 2 mM
EDTA, pH 7.4). Unreacted SATA was removed
by dialysis (Spectrapore tube, 12-14 kD cut-
off) at 4°C overnight. Thioacetylated albumin
was deacetylated by addition of hydroxylamine
(1M, 100 μL/mL BSA, 30 min). Albumin cou-
pling to freshly prepared liposomes was done
by incubation at equal volumes at RT for 8 h.
Addition of N-ethylmaleimide (1:60 mol/mol)
stopped the reaction. Unreacted maleimide
residues were blocked by addition of excess
cysteine as described before.36 Unbound albu-
min was removed by gel filtration on
Sephadex G-100 columns. Protein content was
measured using the Bradford assay according
to the manufacturer’s instructions (Bio-Rad
Laboratories GmbH, Munich, Germany).Cell lines and cell culture
Murine macrophages (RAW 247.6, ATCC
TIB-71) and Lewis lung carcinoma (LLC, ATCC
CRL-1642) cells were cultivated in RPMI 1640
with L-glutamine (10% FBS, 10’000 U/mL
penicillin, 10 mg/mL streptomycin). Murine
NIH 3T3 fibroblasts and pancreatic islet
endothelial MS1 (ATCC CRL-2279) cells were
cultivated in DMEM with 4.5 mg glucose/L
(10% FBS and antibiotics). All cells were
maintained at 37°C/5% CO2 in a humidified
incubator. Flow cytometry and fluorescencemicroscopy
Cells were seeded at a density of 25,000
cells per well in 24-well plates and grown in
RPMI medium for 48 h. Cells were incubated
with medium either containing: (i) DiI-
labeled L; (ii) DiI-labeled PEG-L or (iii) DiI-
labeled BSA-L at concentrations of 10 (8 ng),
50 (20 ng) or 250 (200 ng) nmol SPC/mL lipo-
somes in 300 µL medium for different incuba-
tion times (10 min, 30 min, 1 h, 3 h and 24 h).
Then, cells were washed three times with
PBS. For macrophages, the cell layer was gen-
tly scraped in PBS using a cell scraper to facil-
itate detachment of the cells. For the other cell
types, cells were harvested by trypsinization
and washed once with PBS. Cells were ana-
lyzed by flow cytometry (CyAn 9 ADP Beckman
Coulter, Nyon, Switzerland) to distinguish the
uptake between the three types of liposomes.
Cells were measured for DiI fluorescence and
forward and side scatter were used to gate liv-
ing cells. Liposome uptake was calculated by
dividing the mean log of DiI fluorescence of
liposome-treated viable cells by the mean log
of DiI fluorescence of untreated control cells.
For fluorescence microscopy cells were
washed in PBS after the indicated incubation
times, fixed with formaldehyde (3% in PBS,
AppliChem GmbH, Darmstadt, Germany) and
incubated with DAPI (2 µg/mL in PBS, Roche
Diagnostics GmbH, Mannheim, Germany) for
10 min in order to stain the cell nuclei. The
uptake of liposomes to the different cell types
was examined using an Olympus OBS IX81
microscope (Olympus, Tokyo, Japan). 
Cell viability 
Cell viability was evaluated using the
resazurin method.37 Cells (25,000/well) in 24-
well plates were grown for 30 h. Medium con-
taining increasing concentrations of  1-1000
µM for CL, PEG-CL and BSA-CL or 0.1-10 µM
for ZL, PEG-ZL and BSA-ZL was added for 1 h,
3 h, 24 h or 48 h. Then, cells were washed 3x
with PBS and the 1 h and 3 h treatments were
additionally incubated with RPMI for 23 h or
21 h, respectively, to allow the bisphospho-
nates to take effect. Resazurin (0.5 mL in
medium) was added and after 4 h incubation
at 37°C fluorescence was measured at 590 nm
emission with 540 nm excitation wavelength
in a SpectraMax M5/M5e Reader (Molecular
Devices Corp., Sunnyvale, CA, USA). Cytotoxi -
city (IC50-values) was determined by graphic
extrapolation by plotting drug concentration
against percentage of viable cells and taking
untreated cells as 100% viability. Empty lipo-
somes were not toxic to cells (data not
shown). All measurements were carried out
twice in duplicates. Animal studies
Analysis of macrophage depletion in
spleens was done in C57Bl/6 mice (3/group)
by i.v. injection of 50 μL of DiI-labeled L or
BSA-L. After 1.5 or 6 h the spleens were
removed and immersed in ice cold DMEM
(10% FBS, 4.5 mg glucose/L, 1% antibiotics)
followed by mashing on a 70 μm cell strainer
(Becton Dickinson Labware, Le Pont de Claix,
France) to create a single cell suspension.
After centrifugation (2000 rpm, 5 min) the
pellet was resuspended and filtrated (35 µm
nylon mesh filter, Beckton Dickinson), fol-
lowed by 10 min treatment with red blood cell
lysis buffer (Pharm Lyse™, BD Pharmingen,
San Diego, CA, USA), centrifuged and re-sus-
pended in FACS buffer (2% FCS in PBS). The
CD16/32 Fc blocking antibody (1:300, v/v,
BioLegend, San Diego, CA, USA) was added to
decrease the background signal. Cells were
incubated with the F4/80-APC antibody (1:200
in FACS buffer) for 30 min on ice and immedi-
ately analyzed (CyAn™ 9 ADP). To study
depletion of macrophages, C57Bl/6 mice
(3/group) received 0.2 or 1 mg CL or BSA-CL
by i.p. injection or empty BSA-L as controls.
After 24 h the spleens were removed and cell
suspensions obtained as described above.
Percentage of macrophage depletion was
determined by flow cytometry of F4/80 stained
cells.Statistical analysis
Comparisons among different liposome
preparations were made by the unpaired
Student's t-test using the GraphPad Prism 5.03
software. Differences were termed statistically
significant at P<0.05 and data expressed as
mean±SD.
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Results 
A schematic representation of conventional
liposomes L, poly(ethylene glycol) liposomes
PEG-L and albumin coated  liposomes BSA-L is
shown in Figure 1. 
The structural changes of BSA coated lipo-
somes are summarized in Table 1. The mean
diameter of L was 96.8±1.7 nm with a nearly
neutral ζ-potential. Addition of DSPE-
PEG2000-Mi at 2 mol%, - in contrast to 7.5
mol% used for conventional long circulating
PEG-liposomes38 - increased the diameter by
10 nm and decreased the ζ-potential by 5 mV
as reported previously.38
Covalent coupling of BSA to PEG-L increased
liposome size by about 40 nm and decreased
the ζ-potential to -10 mV, confirming that neg-
atively charged albumin was attached on the
outer liposome surface. Liposome size
changed slightly after storage up to 60 days at
4°C (Table 1). Cell incubation results were
identical with liposomes stored for 60 days,
indicating good liposome stability (data not
shown). The observed size increase of PEG-L
is the direct consequence of pegylation, which
leads to a coating thickness of 5 nm.38 BSA
molecules are negatively charged at physiolog-
ical pH and have either a heart-like shape,
which can be approximated by a triangular
shape,39 a prolate ellipsoid40 or an oblate ellip-
soid,41 depending on the method of structure
analysis used. Calculation of the BSA concen-
tration on the liposome surface based on the
data obtained from the Bradford protein assay
resulted in an average of 64±3 µg BSA/µmol
total lipids, which corresponds to 100-130 BSA
molecules attached to one liposome calculated
as decribed.36 These results are in accordance
with those reported by Thöle et al.42
Encapsulation of the bisphosphonates
resulted in similar sizes as observed with
empty liposomes (Table 2). The encapsulation
rate of 30-33 % (18±2.5 mg/mL for clodronate
and 1.25±0.3 mg for zoledronate) was deter-
mined by radioactive trace labeling (data not
shown). Here, it is noteworthy that the mean
diameter of clodronate liposomes after repeti-
tive extrusion through 400 nm membranes
resulted in a range of 187±88 nm which is con-
siderably smaller than expected. Clodronate
probably interacts with the lipid bilayer in a
way that a condensation effect occurs. To study
the preferential uptake RAW macrophages
were treated with DiI-labeled L, PEG-L and
BSA-L and subsequently analyzed by fluores-
cence microscopy and flow cytometry. As
shown in Figure 2, BSA-L were taken up more
efficiently by the macrophages in a time and
concentration dependent manner. At each time
point the amount of BSA-L taken up was signif-
icantly higher than that of L and PEG-L.
Importantly, there was no difference in uptake
between BSA-L, HSA-L, and MSA-L (Figure 2A,
C) suggesting that the higher uptake of albu-
min coated liposomes was not due to the anti-
genicity of a foreign protein (BSA or HSA on
murine macrophages) but rather due to the
albumin coating. This permits to choose the
albumin independently of the species studied,
without provoking immune responses that
could be induced by antigenic albumin.
Consequently, for the following experiments,
BSA-L were used.  
The flow cytometry results (Figure 2D)
showed that macrophage uptake of BSA-L was
about 17-times higher after 1 h incubation and
remained 4-times higher after 24 h as com-
pared to L. Compared to PEG-L uptake of BSA-
L was 53-times higher after 1 h incubation and
9 times higher after 24 h incubation. These
differences are concentration independent
since no change in uptake was observed at
liposome concentrations of 10 and 50 nmol
SPC/mL (data not shown). The results suggest
that macrophages phagocytose BSA-L at faster
rates than the control liposomes L and PEG-L.
Another aspect highlighted by these results is
that PEG-L uptake by macrophages is signifi-
cantly lower as compared to L, confirming ear-
lier findings.43
Examination of macrophages exposed to
DiI-labeled BSA-L at a higher magnification
(Figure 2B) revealed that DiI was uniformly
distributed on the surface and in the cytoplasm
of the macrophages suggesting that higher
uptake is due to stronger surface binding of
BSA-L and higher phagocytic activity. To evalu-
ate the specificity of BSA-L towards
macrophages, three other cell lines were ana-
lyzed in a comparable set of experiments; can-
cer cells (Lewis lung carcinoma, LLC), fibrob-
lasts (NIH 3T3) and endothelial cells (MS-1).
Uptake of DiI-labeled liposomes was signifi-
cantly lower in these cells when compared to
the macrophages (Figure 3). After 3 h or 24 h
incubation DiI-labeled BSA-L uptake increased
on macrophages between 40- and 220-fold
(Figure 2D), compared to a significantly lower
Article
Table 1. Liposome size and ζ-potential of L, PEG-L and BSA-L. (n=3 for mean particle
size and n=5 for ζ-potential measurements). 
Liposome Mean  Mean diameter Mean diameter Zeta 
diameter (nm) after 30 days (nm) after 60 days(nm)potential (mV)
L 96.8±7 98.2±2.2 97.6±2.8 -1±0.6
PEG – L 111.3±59 110.6±2.6 111.5±2.5 -5.5±0.7
BSA – L 151.1±01 153.3±5.9 158.5±3.9 -10.7±.4
Table 2. Liposome size, encapsulation rate and cytotoxicity (IC50 in µM, see also Figure
5) of bisphosphonates in liposomes (n=3). 
Liposome Mean diameter Encapsulation IC50 IC50 IC50
(nm) rate (%) 3 h 24 h 48 h
CL 186.5±88 30.9 ±2.5 nd nd nd
PEG-CL 184.2±52 30.3±1.0 nd nr 620
BSA-CL 215.8±80 30.3±1.0 200 40 nd
ZL 184.2±54 33.7±1.4 nr 50 4
PEG-ZL 177.5±26 32.8±0.3 nr >50 5.6
BSA-ZL 213.7±97 32.8±0.3 3.6 1 0.225
Figure 1. Schematic representation of conventional liposomes L, poly(ethylene glycol)
liposomes PEG-L and albumin coated liposomes BSA-L. Albumin coating is achieved by
the reaction of activated thiolated albumin with maleimide groups located at the terminal
ends of the poly(ethyleneglycol) chains on the liposome surface.
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1- and 12-fold uptake for the other cells. 
These results confirm the target specificity
of the albumin-coated liposomes towards
macrophages. When analyzed by flow cytome-
try slight differences of liposome uptake
between the cell lines were observed, probably
by virtue of the high sensitivity of the method.
The flow cytometric analysis also showed low
uptake of L by any other cell line, in compari-
son to the macrophages which was further
decreased when BSA-L and PEG-L were used
(Figure 3).
Coating the liposome surface with inert,
biocompatible polymers such as PEG interferes
with the ability of liposomes to interact with
target cells.44,45 Rather, such polymer coating at
saturating concentrations is used to prolong
the blood circulation time of liposomes.38,43-45
The evaluation of our results suggests that
albumin coated liposomes have a 2-fold advan-
tage over uncoated liposomes, on one hand
they are preferred nanoparticles for
macrophages and on the other hand they show
distinctly lower uptake by other cell types. The
in vivo characteristics of the uptake of DiI-
labeled L, PEG-L and BSA-L were assessed in
spleens after intravenous injection (Figure 4).
PEG-L were not used as control since several
studies including ours showed that surface-
grafted PEG reduce opsonization leading to
prolonged blood circulation and reduced
macrophage uptake.43-45 The spleen is the
peripheral reservoir of myeloid cells that is
constantly replenished by bone marrow
myeloid progenitors.2 The analysis of spleen
cells revealed that there was no significant dif-
ference between BSA-L and L concerning the
percentage of targeted macrophages as reflect-
ed by the comparable percent values of F4/80
positive cells ranging from 1.61-2.35% of all
viable splenocytes (Figure 4A, upper right
quadrant). Rather, it seems that macrophages
phagocytose albumin-grafted liposomes at a
highly faster rate compared to other liposome
types. Ninety minutes after liposome injection
Article
Figure 2. In vitro uptake of DiI-labeled liposomes by macrophages. (A) Fluorescence
microscopy images of macrophages incubated with 250 nmol SPC/mL DiI-labeled lipo-
somes at different time points. (B) Uptake after 1h incubation at higher magnification
(640 x). (C) Uptake of DiI-labeled HSA-L and MSA-L after 1h. Red is fluorescence of DiI
and blue is fluorescence of DAPI. (D) Quantification of the cellular uptake of DiI-labeled
liposomes by macrophages by flow cytometry (MFI, mean fluorescence intensity).
Liposome uptake was calculated by dividing the mean log of DiI fluorescence of lipo-
some-treated cells by the mean log of DiI fluorescence of untreated cells.
Figure 3. In vitro evaluation of the uptake
of DiI-labeled liposomes by LLC, NIH
3T3 and MS-1 cells by flow cytometry.
MFI, mean fluorescence intensity; *,
P<0.05; **, P<0.01; ***, P<0.001.
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the population of F4/80+ macrophages which
had taken up DiI-labeled liposomes had
already reached 35.14% (Figure 4A, cells in box
in upper right quadrant) with the BSA-L, while
no such population was found after injection of
L. After 6 h, uptake of L had reached 6.1%,
whereas it had decreased from 35.14-27.5%
with BSA-L. This result indicates that 6 h after
administration of BSA-L macrophages were
already saturated while the rate of phagocyto-
sis of L was still increasing. The decrease of
the DiI-positive macrophage population after
BSA-L treatment between 90 min and 6 h can
possibly be explained by exocytosis of lipo-
somes, whereas exchange of the lipophilic dye
DiI between macrophages and other cells can
be excluded due to the high membrane stabili-
ty of the dye.46 The bar graph shown in Figure
4B recapitulates the macrophage uptake
results of three individual experiments. These
data correlate well with the results from the in
vitro studies and confirm the in vivo efficiency
of BSA-L specifically targeting macrophages.
Hence, we can assume that uptake of albumin
coated liposomes in vivo by macrophages is
faster and occurs at higher avidity compared to
L. Higher uptake of BSA-L by macrophages is
indicative of enhanced delivery of encapsulat-
ed drugs. Thus, we tested the cytotoxic effect
of clodronate and zoledronate containing lipo-
somes on macrophages. In Figure 5, dose-
response curves are presented and the extrap-
olated IC50-values are summarized in Table 2.
BSA-CL were highly toxic to macrophages
showing effects already after 1 h and reaching
an IC50 of 200 µM after 3 h. When compared to
CL, the BSA-L were 15.5 times more effective
in the 24 h assay. Correspondingly, BSA-ZL
liposomes were 50- and 25-times more toxic
after 24 h and 48 h, respectively. The effect of
the zoledronate-liposomes is comparable to
results reported by Shmeeda et al. describing
strong cytotoxic effects of folate targeted lipo-
somes on various cell types expressing folate
receptors at similar IC50 concentrations.47
Thus, our results show that BSA-L deliver
the encapsulated bisphosphonates at faster
rates and more efficiently to macrophages,
causing cytotoxic effects at shorter incubation
times as compared to controls. This is particu-
larly important in the case of conventional clo-
dronate-liposomes, since the quantity of the
administered drug to deplete macrophages is
considerable and in the range of the LD50 for
mice (5.54 mM or 2 mg/20 g mouse weight).24
CL are widely used to deplete macrophages.23-26
Therefore, we tested the macrophage-deplet-
ing efficacy of BSA-CL in mouse spleens and
compared it with CL. Application of 1 mg of
BSA-CL caused 67.6±3.5% depletion of the
F4/80+ population of spleen macrophages after
24 h, whereas after CL treatment depletion
reached only 36.2±9.4%. At 0.2 mg the deple-
tion efficiency of BSA-CL (43.7±3.5%) was
similar to that of 1 mg CL (Figure 6). These
results further confirm that BSA-L are not only
preferred for phagocytosis by macrophages but
that they also deliver drugs more efficiently
and consequently deplete macrophages at
lower clodronate concentrations. 
Discussion
In this study we prepared albumin-coated
liposomes with remarkably increased uptake
properties on macrophages compared to con-
ventional liposomes. Such macrophage specif-
ic liposomes represent an interesting platform
to transport drugs or other compounds effi-
ciently to macrophages, thus opening new
possibilities to treat diseases where
macrophages are involved. Liposomes are
mainly recognized by macrophages equally as
other nanoparticulate carriers and pathogens
by their opsonization, a process where serum
proteins, in particular those of the comple-
Article
Figure 4. In vivo evaluation of the cellular uptake of DiI-labeled liposomes by spleen
macrophages by flow cytometry. In A, a representative logarithmic plot of F4/80+
macrophages (F4/80-APC) versus DiI-labeled liposomes (DiI) is shown. B summarizes the
mean percentage of F4/80+ macrophages which had a 5 times higher DiI fluorescence
intensity (cells in box in upper right quadrant in A) compared to all macrophages select-
ed in the upper right quadrant. DiI-liposome uptake was quantified by determining the
percentage of fluorescent viable macrophages. Non specific fluorescence was eliminated
by gating the signal of non treated mice (logPE=10) and percentages of F4/80+
macrophages were determined by eliminating the signal of unstained samples. The uptake
of the two types of liposomes by macrophages was evaluated by gating the F4/80+
macrophages, which had a 5-fold higher fluorescence (logPE=50) than all positive fluores-
cent macrophages. The bars represent the mean percentage of viable macrophages ± SD,
n=3; **, P<0.01; ***, P<0.001.
Figure 5. Viability of macrophages after treatment with CL and BSA-CL (upper panel) and
ZL, PEG-ZL and BSA-ZL (lower panel) after 1 h, 3 h and 24 h or 48 h drug incubation. 
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ment system, attach to their surfaces to facili-
tate recognition and phagocytosis.27-33
Moreover, the degree of liposome binding and
subsequent ingestion by macrophages
depends on a number of factors including lipid
composition, vesicle type, size and surface
properties. Small unilamellar liposomes deliv-
er drugs more effectively than larger uni- or
multilamellar liposomes and charged lipo-
somes associate more effectively to cells and
deliver their content more efficiently than
neutral liposomes.21,22,48,49 Finally, coating lipo-
some surfaces with proteins or cell surface
specific ligands such as Fc-receptor, comple-
ment, folate, fibronectin, lipoproteins, manno-
syl and galactosyl receptors and others signif-
icantly promote uptake of liposomal content by
macrophages.21,22,50-55 However, many of these
strategies have shortcomings such as system
complexity, production costs and restricted
applications and none of them has been rou-
tinely exploited to increase macrophage
uptake of liposomes for therapeutic interven-
tions. Since the modification of albumin with
a bispecific-coupling molecule as SATA and its
subsequent reaction with maleimide-modified
PEG-lipids are straightforward reactions that
occur in aqueous media, we argue that the
preparation of albumin coated liposomes is an
easy procedure. Potential disadvantages
encountered with the preparation of larger
batches remain to be investigated.
Therefore, it appears that enhancement of
liposome binding and uptake by macrophages
could be achieved by interference with protein
adsorption and reactions with the complement
system. It has been shown that neutral lipo-
somes are poor activators of the complement
system as compared to negatively charged
vesicles.30,56 Besides charge, liposome size and
concentration play also an important role in
complement activation.28,57
Consequently, we reasoned that protein-
coated and thus negatively charged unilamel-
lar liposomes of intermediate sizes would be
phagocytosed more efficiently than conven-
tional liposomes. We achieved this artificial
opsonization by covalent attachment of albu-
min to PEG-modified liposomes. 
Albumin is constantly synthesized in the
liver and its homeostasis is maintained by a
balanced catabolism occurring in all tissues.
Most albumin is degraded in muscle, liver and
kidney.40 Albumin itself is not taken up by
macrophages and it is only upon its covalent
linking to nanoparticulate vesicles such as
liposomes that macrophage uptake occurs.
Thus, possible mechanisms that improve and
accelerate the uptake of albumin coated lipo-
somes are that the protein may accelerate
opsonisation or that binding of the liposomes
to the macrophage cell surface is facilitated
and therefore phagocytosis occurs at higher
rates as compared to uncoated liposomes.
However, the exact mechanisms remain to be
elucidated.
More recently, albumin-liposome conju-
gates have been studied in order to develop
long circulating drug carriers.58,59 In these
reports it was shown that introduction of albu-
min on the surface of conventional PEG-lipo-
somes prolonged circulation in plasma com-
pared to PEG-liposomes. However, in contrast
to our formulations, in these studies albumin
was directly grafted onto the lipid surface of
liposomes containing PEG at the conventional
amounts used for long circulating liposomes.
Thus, the albumin molecules directly attached
to the liposome surface were covered by the
PEG chains, which might prevent or slow
down liposome opsonization. In this study,
bisphosphonates were used as prototype
drugs, however it can be assumed that other
drugs such as protein inhibitors or DNA and
RNA (e.g. siRNA, microRNA and anti-
microRNA) based therapeutics or nanozymes
encapsulated in albumin-liposomes and tar-
geted to macrophages will have similar phar-
maceutical advantages.60-63
In summary, in this study a new nanodrug
carrier platform for specific macrophage deliv-
ery, - albumin coated liposomes -, was devel-
oped and evaluated in vitro and in vivo. These
surface coated liposomes are characterized by
a significantly improved uptake and specifici-
ty towards macrophages, a lower uptake rate
by non myeloid cell types and an enhanced
accumulation in splenic macrophages, as
compared to conventional and pegylated lipo-
somes. Our results indicate that albumin coat-
ed liposomes represent a promising platform
for macro phage specific drug delivery for the
administration of bisphosphonates and other
drugs and compounds. 
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